www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Allergy immunotherapy
    • Healthcare professionals
      • Reweal
      • Webinars
    • Pipeline
    • Clinical trials
    • Clinical data sharing
  • Our company
    • Newsroom
      • Stories
    • Privacy
    • Global presence
    • Organisation
    • History
    • Owners
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Board of Management
      • Board of Directors
      • Annual general meeting
      • Annual general meeting (DK)
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
      • ADR Programme
    • Contact IR
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar

« Back

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

March 02, 2023

PDF Version

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff:

The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 5/2020 of 19 March 2020. The right to share options and performance shares may be achieved in March 2023, provided that ALK achieves the pre-agreed targets for vesting and that the employment relationship with the ALK Group has not been terminated by the Company on objective grounds or terminated.

The final calculations have now been completed, and final allocation of share options and delivery of performance shares have taken place as stated in the attached pdf-file.

ALK-Abelló A/S


For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Maiken Riise Andersen, tel. +45 5054 1434

Attachment

  • FM_06_23UK_02032023
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved